Skip to content

Study · Randomized controlled trial · n = 24 · 2004

5 results

Pharmacokinetic interaction of chloroquine and methylene blue combination against malaria.

Rengelshausen J, Burhenne J, Fröhlich M, Tayrouz Y, Singh SK, Riedel KD, Müller O, Hoppe-Tichy T, Haefeli WE, Mikus G, Walter-Sack I

European journal of clinical pharmacology13 Oct 2004Cited by 57 (Europe PMC)

PMID15619134 (opens in a new tab)DOI10.1007/s00228-004-0818-0 (opens in a new tab)PepBankPUB-15619134
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialPharmacokinetics

    In healthy individuals, adding methylene blue produced a nonsignificant trend toward reduced chloroquine exposure versus placebo co-administration.

    In plain wordsIn healthy people, adding methylene blue tended to reduce chloroquine exposure compared with adding placebo, but the difference was not significant.

    Peptide
    Methylene blue
    Outcome
    No significant changeChloroquine whole blood AUC normalized to weight
    Study

    n = 24

    Comparator
    Chloroquine plus placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    130 mg twice daily · oral · 3 daysAs given in this study (human).

    Measurements

    Chloroquine whole blood AUC(0-24 h)/BW
    249 h mug l(-1) kg(-1)
    with methylene blue, +/-98.2
    Chloroquine whole blood AUC(0-24 h)/BW
    315 h mug l(-1) kg(-1)
    with placebo, +/-65.0

    Source sentences

    Summary
    During methylene blue exposure, the area under the chloroquine whole blood concentration-time curve normalized to body weight (AUC(0-24 h)/BW) yielded a trend of reduction (249+/-98.2 h mug l(-1) kg(-1) versus 315+/-65.0 h mug l(-1) kg(-1), P=0.06).
    1 context sentence
    Summary · context
    In a randomized, placebo-controlled, parallel group design, a 3-day course of therapeutic oral doses of chloroquine (total 2.5 g in male, 1.875 g in female participants) with oral co-administration of placebo or 130 mg methylene blue twice daily for 3 days was administered to 24 healthy individuals.
  2. 02HumanRandomized controlled trialPharmacokinetics

    In healthy individuals, adding methylene blue reduced desethylchloroquine exposure by 35% versus placebo co-administration.

    In plain wordsIn healthy people, adding methylene blue reduced exposure to the chloroquine metabolite by 35% compared with adding placebo.

    Peptide
    Methylene blue
    Outcome
    DecreaseDesethylchloroquine AUC normalized to weight
    Study

    n = 24

    Comparator
    Chloroquine plus placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    130 mg twice daily · oral · 3 daysAs given in this study (human).

    Measurements

    Desethylchloroquine AUC(0-24 h)/BW reduction
    35%
    with methylene blue versus placebo
    Desethylchloroquine AUC(0-24 h)/BW
    104 h mug l(-1) kg(-1)
    with methylene blue, +/-40.3
    Desethylchloroquine AUC(0-24 h)/BW
    159 h mug l(-1) kg(-1)
    with placebo, +/-66.6

    Source sentences

    Summary
    The AUC(0-24 h)/BW of desethylchloroquine was reduced by 35% (104+/-40.3 h mug l(-1) kg(-1) versus 159+/-66.6 h mug l(-1) kg(-1), P=0.03)
    1 context sentence
    Summary · context
    In a randomized, placebo-controlled, parallel group design, a 3-day course of therapeutic oral doses of chloroquine (total 2.5 g in male, 1.875 g in female participants) with oral co-administration of placebo or 130 mg methylene blue twice daily for 3 days was administered to 24 healthy individuals.
  3. 03HumanRandomized controlled trialPharmacokinetics

    In healthy individuals, adding methylene blue did not significantly change the chloroquine to desethylchloroquine metabolic ratio versus placebo co-administration.

    In plain wordsIn healthy people, adding methylene blue did not significantly change the chloroquine to metabolite ratio compared with adding placebo.

    Peptide
    Methylene blue
    Outcome
    No significant changeChloroquine to desethylchloroquine metabolic ratio
    Study

    n = 24

    Comparator
    Chloroquine plus placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    130 mg twice daily · oral · 3 daysAs given in this study (human).

    Measurements

    Chloroquine to desethylchloroquine metabolic ratio
    2.25 ratio
    first value of the reported comparison, +/-0.49
    Chloroquine to desethylchloroquine metabolic ratio
    1.95 ratio
    second value of the reported comparison, +/-0.42

    Source sentences

    Summary
    whereas the metabolic ratio between chloroquine and desethylchloroquine remained unchanged (2.25+/-0.49 versus 1.95+/-0.42, P=0.17).
    1 context sentence
    Summary · context
    In a randomized, placebo-controlled, parallel group design, a 3-day course of therapeutic oral doses of chloroquine (total 2.5 g in male, 1.875 g in female participants) with oral co-administration of placebo or 130 mg methylene blue twice daily for 3 days was administered to 24 healthy individuals.
  4. 04HumanRandomized controlled trialPharmacokinetics

    In healthy individuals, adding methylene blue did not significantly change chloroquine renal clearance versus placebo co-administration.

    In plain wordsIn healthy people, adding methylene blue did not significantly change kidney clearance of chloroquine compared with adding placebo.

    Peptide
    Methylene blue
    Outcome
    No significant changeChloroquine renal clearance
    Study

    n = 24

    Comparator
    Chloroquine plus placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    130 mg twice daily · oral · 3 daysAs given in this study (human).

    Source sentences

    Summary
    The renal clearance of chloroquine and the ratio between chloroquine in whole blood and plasma remained unchanged (P>0.1).
    1 context sentence
    Summary · context
    In a randomized, placebo-controlled, parallel group design, a 3-day course of therapeutic oral doses of chloroquine (total 2.5 g in male, 1.875 g in female participants) with oral co-administration of placebo or 130 mg methylene blue twice daily for 3 days was administered to 24 healthy individuals.
  5. 05HumanRandomized controlled trialPharmacokinetics

    In healthy individuals, adding methylene blue did not significantly change the chloroquine whole blood to plasma ratio versus placebo co-administration.

    In plain wordsIn healthy people, adding methylene blue did not significantly change chloroquine's blood to plasma ratio compared with adding placebo.

    Peptide
    Methylene blue
    Outcome
    No significant changeChloroquine whole blood to plasma ratio
    Study

    n = 24

    Comparator
    Chloroquine plus placebo
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    130 mg twice daily · oral · 3 daysAs given in this study (human).

    Source sentences

    Summary
    The renal clearance of chloroquine and the ratio between chloroquine in whole blood and plasma remained unchanged (P>0.1).
    1 context sentence
    Summary · context
    In a randomized, placebo-controlled, parallel group design, a 3-day course of therapeutic oral doses of chloroquine (total 2.5 g in male, 1.875 g in female participants) with oral co-administration of placebo or 130 mg methylene blue twice daily for 3 days was administered to 24 healthy individuals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.